Primary prevention in antiphospholipid antibody carriers

Area of Science:

• Rheumatology
• Immunology
• Hematology

Background:

• Antiphospholipid antibody (aPL) positivity is common in individuals without thrombosis or pregnancy complications, posing a clinical challenge.
• Antiphospholipid syndrome (APS) diagnosis and management remain areas of active research.
• Primary prophylaxis for thrombotic events in aPL carriers is an unresolved issue.

Purpose of the Study:

• To focus on primary prophylaxis strategies for thrombotic events in antiphospholipid antibody (aPL) carriers.
• To identify patient subgroups who may benefit from thromboprophylaxis.
• To evaluate the role of aspirin and hydroxychloroquine in preventing thrombosis and organ damage in aPL-positive patients with SLE.

Main Methods:

• Review of current literature and clinical guidelines regarding aPL carriers and thromboprophylaxis.
• Analysis of risk factors associated with thrombotic events in aPL-positive individuals.
• Discussion of therapeutic strategies including low-dose aspirin and hydroxychloroquine.

Main Results:

• Patients with high-risk aPL profiles, cardiovascular risk factors, or a history of obstetric APS (OAPS) are candidates for thromboprophylaxis.
• Concomitant diagnosis of systemic lupus erythematosus (SLE) in aPL-positive individuals is a key consideration for prophylaxis.
• The study advocates for thromboprophylaxis in specific high-risk aPL carrier groups.

Conclusions:

• Primary thromboprophylaxis should be considered for aPL carriers with high-risk profiles, cardiovascular risk factors, SLE, or a history of OAPS.
• Chronic thromboprophylaxis with low-dose aspirin and hydroxychloroquine is recommended for aPL-positive SLE patients.
• These interventions aim to prevent thrombotic events and mitigate early organ damage in at-risk populations.